ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.
Open access · greenAbstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 3 pooled it
14.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.Journal for immunotherapy of cancer · 2026Guideline
- Global research trends and hotspots in human immunodeficiency virus-associated cervical cancer (1990-2025): a multi-database bibliometric analysis.Frontiers in immunology · 2026Pooled it
- 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).Breast (Edinburgh, Scotland) · 2024Guideline
- Exacerbation of CMV and Nontuberculous Mycobacterial Infections Following PD-1 Blockade for HIV-Associated Kaposi Sarcoma.Open forum infectious diseases · 2024Trial
- Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy.Open forum infectious diseases · 2024Trial
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Safety, Immunovirologic, and Central Nervous System Effects of PD-1 Inhibition in People With HIV Without Malignancy.The Journal of infectious diseases · 2026Article
- Hepatic and Pancreatobiliary Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Multidisciplinary Approach.Biomedicines · 2026Review
- Article
- Brief Report: Real-World Outcomes in Patients Living With Human Immunodeficiency Virus and Lung Cancer Treated With Immune Checkpoint Inhibitors.JTO clinical and research reports · 2026Article
- Population Analysis and Immunologic Landscape of Melanoma in People Living with HIV.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Article
- Immunotherapy for Melanoma in Patients with Altered Immune Systems: Unique Challenges and Clinical Considerations.Advances in therapy · 2026Review
- Immune checkpoint inhibitors in infectious diseases: therapeutic reinvigoration, immunopathology, and precision targeting.Frontiers in immunology · 2026Review
- Real-world efficacy and safety of PD-1 inhibitors in patients living with HIV and cancer: a retrospective cohort study.Frontiers in oncology · 2026Article
- Virus-driven remodeling of the immune microenvironment and response to immune checkpoint inhibitors: the infection- immunity-cancer crosstalk.Frontiers in immunology · 2026Review
- Incidence of severe immune-related adverse reactions in patients with HIV and cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in oncology · 2026Review
- PD-1/PD-L1 blockade in HIV-associated advanced lung cancer: from mechanisms to clinical practice.Frontiers in immunology · 2026Review
- Melanoma in people living with HIV: antigen-presentation loss, spatial immune escape, and inclusive immunotherapy trials.Frontiers in immunology · 2026Review
- Nivolumab + Doxorubicin, Vinblastine, and Dacarbazine in HIV-Associated Advanced-Stage Classic Hodgkin Lymphoma.JCO oncology advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
81 authors at 20 institutions in 8 countries.
Talal El ZarifDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-4507-2396
Amin H NassarYale University School of Medicine, New Haven, CT.ORCID 0000-0002-8084-9105
Elio AdibDana-Farber Cancer Institute, Boston, MA.
Bailey G FitzgeraldTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-5566-5953
Jiaming HuangDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-4785-5674
Tarek H MouhieddineTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-1190-5978
Paul G RubinsteinDivision of Hematology/Oncology, Ruth M. Rothstein CORE Center, Cook County Health and Hospital Systems (Cook County Hospital), University of Illinois Chicago Cancer Center, Chicago, IL.ORCID 0000-0002-0724-461X
Taylor NonatoMoores Cancer Center, The University of California San Diego, La Jolla, CA.
Rana R McKayMoores Cancer Center, The University of California San Diego, La Jolla, CA.ORCID 0000-0002-0581-7963
Mingjia LiDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0002-3910-4179
Arjun MittraDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0001-9572-3495
Dwight H OwenDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0002-6598-4886
Robert A BaiocchiDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Michael LorentsenDivision of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0003-0144-698X
Christopher DittusDivision of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0002-9794-7908
Nazli DizmanYale University School of Medicine, New Haven, CT.ORCID 0000-0002-3907-8513
Adewunmi FalohunUniversity of Texas MD Anderson Cancer Center, Houston, TX.
Noha Abdel-WahabUniversity of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-7621-9266
Adi DiabUniversity of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-0153-0244
Anand BankapurDepartment of Surgery, Division of Urology, Cook County Health, Chicago, IL.
Alexandra ReedDepartment of Surgery, Division of Urology, Cook County Health, Chicago, IL.
Chul KimLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.ORCID 0000-0003-0191-8684
Aakriti AroraMedstar/Georgetown-Washington Hospital Center, Washington, DC.
Neil J ShahMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-5752-6212
Edward El-AmIndiana University School of Medicine, Indiana Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN.
Elie KozailyIndiana University School of Medicine, Indiana Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN.ORCID 0000-0002-6719-0422
Wassim AbdallahDepartment of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA.ORCID 0000-0001-9715-7108
Ahmad Al-HaderIndiana University School of Medicine, Indiana Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN.
Batool Abu GhazalKansas University Cancer Center, Kansas City, KS.
Anwaar SaeedKansas University Cancer Center, Kansas City, KS.ORCID 0000-0001-8024-9401
Claire DrolenUniversity of California Los Angeles, Los Angeles, CA.ORCID 0000-0002-8813-7751
Melissa G LechnerUniversity of California Los Angeles, Los Angeles, CA.ORCID 0000-0002-4744-6566
Alexandra DrakakiUniversity of California Los Angeles, Los Angeles, CA.ORCID 0000-0001-8865-3548
Javier Baena12 de Octubre University Hospital, Madrid, Spain.
Caroline A NebhanDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-9402-7284
Tarek HaykalDepartment of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC.ORCID 0000-0002-8637-7292
Michael A MorseDepartment of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC.
Alessio CortelliniDepartment of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom.ORCID 0000-0002-1209-5735
David J PinatoDepartment of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom.ORCID 0000-0002-3529-0103
Alessia Dalla PriaDepartment of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom.ORCID 0000-0002-0209-4245
Evan HallUniversity of Washington, Seattle, WA.ORCID 0000-0002-0305-7745
Veli BakalovAllegheny Health Network, Pittsburgh, PA.
Nathan BaharyAllegheny Health Network, Pittsburgh, PA.ORCID 0000-0001-7317-9118
Aarthi RajkumarSeidman Cancer Center, University Hospitals, Cleveland, OH.
Ankit ManglaSeidman Cancer Center, University Hospitals, Cleveland, OH.ORCID 0000-0002-6789-4315
Vishal ShahMayo Clinic, Phoenix, AZ.ORCID 0000-0002-6962-5637
Parminder SinghMayo Clinic, Phoenix, AZ.
Frank Aboubakar NanaUniversité Catholique de Louvain (UCLouvain), Brussels, Belgium.ORCID 0000-0002-6205-5053
Nerea Lopetegui-LiaTaussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.ORCID 0000-0002-6207-2371
Danai DimaTaussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.ORCID 0000-0002-3587-7975
Ryan W DobbsDivision of Hematology/Oncology, Ruth M. Rothstein CORE Center, Cook County Health and Hospital Systems (Cook County Hospital), University of Illinois Chicago Cancer Center, Chicago, IL.ORCID 0000-0003-1397-7307
Pauline FunchainTaussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.ORCID 0000-0002-7568-8626
Rabia SaleemStephenson Cancer Center, University of Oklahoma, Oklahoma City, OK.
Rachel WoodfordMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.ORCID 0000-0002-9470-314X
Georgina V LongMelanoma Institute Australia, Faculty of Medicine & Health, Charles Perkins Centre, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.ORCID 0000-0001-8894-3545
Alexander M MenziesMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.ORCID 0000-0001-5183-7562
Carlo GenovaUO Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.ORCID 0000-0003-3690-8582
Giulia BarlettaUO Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Sonam PuriHuntsman Cancer Institute, University of Utah, Salt Lake City, UT.ORCID 0000-0001-8068-5051
Vaia FlorouHuntsman Cancer Institute, University of Utah, Salt Lake City, UT.ORCID 0000-0001-5558-753X
Dame IdossaUniversity of California San Francisco, San Francisco, CA.
Maristella SaponaraDivision of Melanoma and Sarcoma Medical Treatment, IEO European Institute of Oncology IRCCS Milan, Milan, Italy.
Paola QueiroloDivision of Melanoma and Sarcoma Medical Treatment, IEO European Institute of Oncology IRCCS Milan, Milan, Italy.
Giuseppe LambertiDepartment of Experimental, Diagnostic and Specialty Medicine, Università di Bologna, Bologna, Italy.ORCID 0000-0003-3069-7630
Alfredo AddeoSwiss Cancer Center Leman, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.ORCID 0000-0003-0988-0828
Melissa BersanelliUniversity Hospital of Parma, Parma, Italy.ORCID 0000-0002-6527-6281
Dory FreemanDana-Farber Cancer Institute, Boston, MA.
Wanling XieDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-5995-8000
Erin G ReidMoores Cancer Center, The University of California San Diego, La Jolla, CA.ORCID 0000-0003-4029-8641
Elizabeth Y ChiaoUniversity of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-5752-2916
Elad SharonDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-0044-9719
Douglas B JohnsonDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-6390-773X
Ramya RamaswamiHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0001-5709-4675
Mark BowerDepartment of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom.ORCID 0000-0002-4077-6351
Brinda EmuYale University School of Medicine, New Haven, CT.
Thomas U MarronTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
Toni K ChoueiriDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-9201-3217
Lindsey R BadenBrigham and Women's Hospital, Boston, MA.
Kathryn LurainHIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-5794-7292
Guru P SonpavdeAdventHealth Cancer Institute, Orlando, FL.ORCID 0000-0002-1010-9611
Abdul Rafeh NaqashStephenson Cancer Center, University of Oklahoma, Oklahoma City, OK.ORCID 0000-0001-7622-720X
Dana-Farber Cancer Institute · USThe Ohio State University · USThe University of Texas MD Anderson Cancer Center · USCleveland Clinic · USHammersmith Hospital · GBIcahn School of Medicine at Mount Sinai · USIndiana University Health · USResearch Institute Hospital 12 de Octubre · ESThe University of Sydney · AUUniversity of California, Los Angeles · USUniversity of California San Diego · USYale University · USAllegheny Health Network · USBrigham and Women's Hospital · USDuke Medical Center · USEuropean Institute of Oncology · ITJohn H. Stroger, Jr. Hospital of Cook County · USMayo Clinic Hospital · USNational Institutes of Health · USOklahoma State University Oklahoma City · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MVOLT (Vanderbilt Oncology Training Program)T32CA217834 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Douglas B Johnson · 2018 to 2026
$2.7MMechanisms of Thyroid Autoimmunity in Checkpoint ImmunotherapyK08DK129829 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LECHNER, MELISSA G · 2021 to 2025
$878kImmune-Related Adverse Events in Melanoma Patients Receiving Adjuvant Immune Checkpoint Inhibitor TherapyK01AI163412 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HASSAN, NOHA ABDELWAHAB HASSAN ALI · 2021 to 2025
$569kNCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA217834NIAID NIH HHS K01 AI163412NIDDK NIH HHS K08 DK129829
Abstract
purposeCompared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer.
methodsThis retrospective study included PWH treated with anti-PD-1- or anti-PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC).
resultsAmong 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti-PD-1/anti-PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts ≥200 cells/µL, and 94% (179/190) had HIV viral load <400 copies/mL. Twenty percent (79/390) had any grade immune-related adverse events (irAEs) and 7.7% (30/390) had grade ≥3 irAEs. ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11% (HNSCC). In the matched mNSCLC cohort (61 PWH
conclusionAmong PWH, ICIs demonstrated differential activity across cancer types with no excess toxicity. Safety and activity of ICIs were similar between matched cohorts of PWH and PWOH with mNSCLC.
Indexed as
Carcinoma, HepatocellularCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsHIV InfectionsLiver NeoplasmsLung NeoplasmsFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedRetrospective StudiesSquamous Cell Carcinoma of Head and NeckImmune Checkpoint Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.